UK trial rules at six months show 7-day approvals for minor edits

Six months after the UK's new clinical trials regulations came into force, the Medicines and Healthcare products Regulatory Agency (MHRA) says a fast track for low-risk trial changes is averaging seven days from start to finish, and that between 3% and 5% of new trial applications still fail at the first hurdle for avoidable reasons.

The figures come from a post on the MHRA Inspectorate blog published on 28 October 2026 by Anthony Carter and Kingyin Lee. The post reviews the first six months of the regulations and lists the mistakes that most often slow applications down.

What changed on 28 April

The new regulations took effect on 28 April 2026. The MHRA describes them as "a more flexible and risk-proportionate approach to clinical trial assessment."

Sponsors now submit a single clinical trial application through the Integrated Research Application System (IRAS). That one application is reviewed by both the MHRA and a Research Ethics Committee (REC). Before the reforms, the combined review system already linked the two, and the regulations put that joint approach into law.

The blog lists improvements sponsors have seen in the first six months:

• updates for applicants as their application moves through assessment
• up to 60 days to respond to a request for information (RFI)
• final decisions within 10 days of receiving an RFI response
• expert consultation with the Commission on Human Medicines for higher-risk investigational medicinal products (IMPs), including some advanced therapy IMPs

The timelines

According to the blog, the validation stage can take up to seven days. Once validated, an application enters assessment, which can take up to 30 calendar days until a decision is communicated. The MHRA says this "is often completed faster when the submission is complete and of good quality."

If the MHRA or the REC needs more information, it issues an RFI. The sponsor then has up to 60 days to respond, and the final decision comes within 10 days of the response.

Why applications fail validation

The blog says that in many cases delays happen "for relatively simple reasons, such as missing documentation, unsigned forms or files that don't meet Optical Character Recognition (OCR) requirements." Approximately 3 to 5% of applications fail validation for these reasons.

The MHRA's separate guidance on common validation issues adds examples, including missing or invalid application forms, choosing the wrong submission category, and uploading scanned PDFs that are not OCR-enabled.

The most common reason for delay in general, the blog says, is incomplete documentation. An inadequate package can trigger an RFI from the MHRA, the REC or both, which delays approval.

Common pharmaceutical problems

The MHRA lists the pharmaceutical issues it sees most often:

• IMPs or placebos missing from the medicine information form
• missing justifications for how IMPs are labelled
• unclear, incomplete or missing manufacturing site information
• missing or incomplete Good Manufacturing Practice information or Qualified Person declarations

Common medical problems

Three medical issues come up repeatedly.

Contraception. Applications sometimes do not follow Clinical Trials Facilitation Group guidance, particularly on how long contraception is needed after the final dose of the IMP.

Emergency unblinding. Protocols must say clearly how investigators can find out which treatment a participant received in a medical emergency, and must make sure investigators keep the primary right to break the blind when necessary.

Safety reporting. Protocols should state that investigators must report serious adverse events to sponsors within 24 hours.

For participants, these points matter directly. Emergency unblinding lets doctors treat someone safely if something goes wrong, and fast reporting of serious adverse events is how sponsors and regulators spot safety problems early. Our guide to placebo and blinding in clinical trials explains how blinding works.

Common non-clinical problems

On the laboratory and animal data that support a first trial in people, the MHRA lists:

• too little information about the main safety studies, including whether they were carried out in a country that is part of the OECD's Mutual Acceptance of Data system
• no justification, from a safety perspective, for the starting and maximum doses in humans
• missing descriptions of the analytical methods used in pharmacokinetic and toxicology studies

Notifiable trials

The regulations include a notification route for lower-risk trials. The MHRA says sponsors using it should check, before they submit, that they:

• selected the correct notifiable trial condition
• have a complete supporting first-in-human programme where relevant
• submitted the same versions of the protocol, Investigator's Brochure and IMP dossier as were sent to any other regulator they are relying on
• avoided adding UK-specific requirements that would need extra MHRA assessment
• followed standard quality requirements, including labelling guidance

Route B for low-risk changes

Once a trial is running, sponsors often need to change it. Significant changes are called substantial modifications. Since 28 April 2026, sponsors must use the Route B process for substantial modifications that meet its eligibility criteria. The blog says "there is no alternative route for eligible modifications."

The key condition is that, after reasonable enquiries, the sponsor is not aware of any significant new safety concerns about the IMP since the trial was approved.

After a six-month pilot, the MHRA reports an average validation time of 3 days and an average review time of 4 days. End to end, approval took 7 days on average.

The regulatory maximum for Route B is 21 days, made up of up to 7 days for validation and up to 14 days for review.

Most objections, the MHRA says, come when proposed changes affect safety information, especially changes to the Reference Safety Information that add new expected adverse reactions. The Reference Safety Information is the list used to decide whether a serious reaction was expected, which in turn affects how quickly it must be reported.

Before submitting under Route B, sponsors should check that the change fits a published Route B category, that the confirmation form is complete, that the cover letter clearly describes the changes and states the Route B route, and that the change does not require reassessment of the trial's safety profile or risk-benefit balance.

Where this fits

The six-month update came two weeks after the MHRA published its Strategy 2030, which promises initial assessment of first-in-human trials within 14 days and an AI-enabled protocol checker to help sponsors avoid common grounds for non-acceptance. We cover that in our article on MHRA Strategy 2030.

The blog's message lines up with the strategy. Many delays are avoidable, and the MHRA wants applications that are right first time.

What it means for patients

For people looking for a trial, faster approvals and faster changes can mean trials open sooner and adapt more quickly to new safety information. The regulations keep ethics review and MHRA assessment in place for every trial, and the blog's emphasis on contraception advice, emergency unblinding and 24-hour safety reporting reflects protections for participants.

UK trials are listed on registries including the Be Part of Research service. Our guide on how to find and join a clinical trial explains how to search and what to ask.

What sponsors should do now

The MHRA's advice is practical:

• read the published guidance and checklists before submitting
• make sure every required document is included, signed and OCR-readable
• check contraception, unblinding and safety reporting wording in the protocol
• justify starting and maximum doses from a safety perspective
• use Route B where eligible, with complete forms and matching document versions

The MHRA's Clinical Trials Hub on GOV.UK collects the latest guidance, and the agency's clinical trials helpline is at clintrialhelpline@mhra.gov.uk.

Related reading

• MHRA Strategy 2030 targets faster approvals and trials
• Placebo and blinding in clinical trials explained

This article is for general information and is not medical advice. Please talk to your own doctor before joining a trial or changing any treatment.